Some boards of appeal have considered recognising specific therapeutic uses as patentable in principle to be problematic where they differ from the prior art merely in terms of the dosage regimen. In G 2/08 date: 2010-02-19 (OJ 2010, 456), the Enlarged Board addressed this issue in detail.